Stock SYBX SYNLOGIC, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Synlogic, Inc. Share Price

Equities

SYBX

US87166L2097

Biotechnology & Medical Research

Delayed Nasdaq
Other stock markets
 16:42:23 17/01/2025 GMT 		5-day change 1st Jan Change
1.450 USD 0.00% Intraday chart for Synlogic, Inc. -1.37% +3.57%
12-23 Synlogic, Inc. Announces the Appointment of Mary Beth Dooley as Principal Executive Officer, Effective January 1, 2025 CI
12-23 Synlogic, Inc. Announces the Appointment of Mary Beth Dooley as Principal Financial Officer, Effective January 1, 2025 CI

Valuation: Synlogic, Inc.

Capitalization 16.96M 16.47M 15.45M 13.86M 24.41M 1.47B 27.27M 189M 70.25M 601M 63.63M 62.3M 2.63B P/E ratio 2024 *
-0.54x
P/E ratio 2025 * -3.09x
Enterprise value 59.36K 57.66K 54.09K 48.52K 85.45K 5.14M 95.44K 661K 246K 2.1M 223K 218K 9.22M EV / Sales 2024 *
-
EV / Sales 2025 * -
Free-Float
83.8%
Yield 2024 *
-
Yield 2025 * -
More valuation ratios * Estimated data

Chart: Synlogic, Inc.

Dynamic Chart

Latest news: Synlogic, Inc.

Synlogic, Inc. Announces the Appointment of Mary Beth Dooley as Principal Executive Officer, Effective January 1, 2025 12-23 CI
Synlogic, Inc. Announces the Appointment of Mary Beth Dooley as Principal Financial Officer, Effective January 1, 2025 12-23 CI
Synlogic, Provides Information to the Shareholders 12-05 CI
Synlogic, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 11-12 CI
Synlogic, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 08/08/24 CI
Synlogic, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 14/05/24 CI
Synlogic, Inc. Announces Board Changes 21/03/24 CI
North American Morning Briefing : Investors -2- 21/03/24 DJ
HC Wainwright Upgrades Synlogic to Neutral From Sell 20/03/24 MT
Earnings Flash (SYBX) SYNLOGIC Reports Q4 Revenue $2.8M 19/03/24 MT
Synlogic, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 19/03/24 CI
Synlogic, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 19/03/24 CI
Synlogic Board Approves Poison Pill Defense After Unsolicited Accumulation of Shares 20/02/24 MT
More news

Analysts' recommendations: Synlogic, Inc.

HC Wainwright Upgrades Synlogic to Neutral From Sell 20/03/24 MT
Chardan Downgrades Synlogic to Neutral From Buy on Early Termination of Synpheny-3 Trial 09/02/24 MT
Leerink Partners Downgrades Synlogic to Market Perform From Outperform, Adjusts PT to $1 From $6 09/02/24 MT
HC Wainwright Downgrades Synlogic to Sell From Buy 09/02/24 MT
Alliance Global Partners Starts Coverage on Synlogic with Buy Rating, $30 Price Target 11/12/23 MT
More recommendations

Press Releases: Synlogic, Inc.

Synlogic : Management Change/Compensation Form 8 K 12-23 PU
Synlogic : Reports Third Quarter 2024 Financial Results Form 8 K 11-12 PU
Synlogic Reports Third Quarter 2024 Financial Results 11-12 AQ
Synlogic Reports Second Quarter 2024 Financial Results 08/08/24 AQ
Synlogic Reports First Quarter 2024 Financial Results 14/05/24 AQ
More press releases

Quotes and Performance

1 week-1.37%
Current month+3.57%
3 months+2.11%
6 months-12.09%
Current year+3.57%
More quotes

Course Extremes

1 week
1.36
Extreme 1.36
1.47
1 month
1.36
Extreme 1.36
1.59
Current year
1.36
Extreme 1.36
1.52
1 year
1.22
Extreme 1.22
3.73
3 years
1.22
Extreme 1.22
39.75
5 years
1.22
Extreme 1.22
76.65
10 years
1.22
Extreme 1.22
345.00
More quotes

Managers and Directors: Synlogic, Inc.

Director TitleAgeSince
Mary Dooley CEO
 Chief Executive Officer 44 31/12/2024
Caroline Kurtz PRN
 Corporate Officer/Principal - 07/03/2021
Brendan St Amant LAW
 General Counsel - 30/06/2021
Manager TitleAgeSince
Richard Shea BRD
 Director/Board Member 73 27/08/2017
Peter Barrett CHM
 Chairman 73 27/08/2017
Ed Mathers Mathers BRD
 Director/Board Member 65 30/09/2012
More insiders

ETFs: Synlogic, Inc.

Name Weight AuM 1st Jan change Investor Rating
VANGUARD US TOTAL MARKET SHARES INDEX ETF ETF Vanguard US Total Market Shares Index ETF
0.00% 293,477 M€ +1.26% -
More ETFs: Synlogic, Inc.

Other Biotechnology & Medical Research

Add to a list
Add to a list

0 selected

To use this feature you must be a member
Log inSign up
 Change 5d. change 1-year change 3-years change Capi. ($)
SYNLOGIC, INC. Stock Synlogic, Inc.
0.00%-1.37%-55.45%-94.89%16.96M
LONZA GROUP AG Stock Lonza Group AG
+1.20%+0.07%+54.47%-16.48%43.42B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+0.55%-2.51%-6.04%-18.22%35.88B
CELLTRION, INC. Stock Celltrion, Inc.
-1.10%-2.96%+0.80%+14.95%26.89B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
-1.22%-8.89%-19.78%-21.84%16.72B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
-1.60%-1.45%+61.83%+69.63%16.36B
MODERNA, INC. Stock Moderna, Inc.
+0.89%-19.31%-66.03%-81.73%12.99B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+0.24%+3.87%+9.03%-19.63%12.09B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+1.32%-2.55%+20.03%+100.86%10.45B
QIAGEN N.V. Stock Qiagen N.V.
+0.77%+3.31%+0.17%-7.57%10.2B
Average +0.13%-4.21%-0.10%-7.49% 18.5B
Weighted average by Cap. +0.25%-3.67%+12.50%-2.80%
See all sector performances

Financials

2024 *2025 *
Net sales - -
Net income -32.9M -31.96M -29.98M -26.89M -47.36M -2.85B -52.9M -367M -136M -1.17B -123M -121M -5.11B -5.7M -5.54M -5.19M -4.66M -8.21M -494M -9.16M -63.52M -23.61M -202M -21.39M -20.94M -885M
Net Debt -16.9M -16.42M -15.4M -13.81M -24.33M -1.46B -27.17M -188M -70M -599M -63.41M -62.08M -2.62B -11.7M -11.37M -10.66M -9.56M -16.84M -1.01B -18.81M -130M -48.46M -415M -43.9M -42.98M -1.82B
More financial data * Estimated data

Company Profile

Logo Synlogic, Inc.
Synlogic, Inc. is a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases. The Company is focused on rare metabolic disorders, with its lead program, labafenogene marselecobac (SYNB1934), studied in Synpheny-3, a global, pivotal Phase 3 study for patients with phenylketonuria (PKU), and SYNB1353, a potential treatment for homocystinuria (HCU). The Company's early-stage pipeline includes product candidates for enteric hyperoxaluria, gout, and cystinuria, and has been fueled by a reproducible, proprietary approach that creates gastrointestinal (GI)-restricted, oral medicines with new enzymatic pathways designed to consume or produce specific biological targets. It designs, develops and manufactures these drug candidates, which are produced by applying genetic engineering to well-characterized probiotics. The Company’s preclinical work includes additional metabolic disease research.
Employees
6
Sector
Biotechnology & Medical Research
Calendar
12/03/2025 - Q4 2024 Earnings Release (Projected)
More about the company

Quotes

Date Price Change Volume
17/01/25 1.450 $ 0.00% 7,432
16/01/25 1.450 $ -0.68% 14,011
15/01/25 1.460 $ +1.39% 12,880
14/01/25 1.440 $ +1.41% 33,786
13/01/25 1.420 $ -3.41% 16,178

Delayed Quote Nasdaq, January 17, 2025 at 04:42 pm

More quotes

Income Statement and Estimates

income-statement-evolution-chart SYNLOGIC-INC More financial data

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
1.450USD
Average target price
1.000USD
Spread / Average Target
-31.03%
Consensus
Profit revisions
estimates-change-chart SYNLOGIC-INC Estimate revisions

Quarterly revenue - Rate of surprise

quality-estimates-chart SYNLOGIC-INC Company calendar
  1. Stock Market
  2. Equities
  3. SYBX Stock
United States

MarketScreener is also available in this country: United States.

Switch edition
Stay in the current country edition